Phenox Preset Stentriever Demonstrates Benefits of Longer Device for Neurothrombectomy

August 3, 2021—Phenox GmbH, a manufacturer of stentrievers for mechanical thrombectomy based in Bochum, Germany, announced the publication of results of an evaluation of the benefit of choosing the company’s longer stentriever device in mechanical thrombectomy. The study by Carmen Serna Candel, MD, et al is available online in Frontiers in Neurology.

The investigators examined the outcomes of the company’s Preset 4x20 versus outcomes using the Preset 5x40 stentriever, the latest addition to the company’s portfolio

According to Phenox, the results reaffirm that using the longer device is better for patient outcomes with a significant improvement in recanalization rates as well as improved mortality rates. and fewer passes required to full recanalization. The company reported that the investigators found first-pass success was seen in 68.4% of procedures with the Preset 5x40 versus 48.7% with the Preset 4x20.

“We, in the Phenox engineering team, are delighted to offer to the market another device that will improve the outcomes of patients. And now, with this data, the 5x40 Preset has proven its value,” commented Ralf Hannes, the company’s Managing Partner, in the announcement.

Prof. Hermann Monstadt, PhD, who is Managing Partner of Phenox, added, “We are proud to continue to innovate the neurovascular market and the most important aspect of developing new devices is clinical outcomes. This publication is a testament to how we work with feedback from physicians to provide devices to improve patients’ lives.”